The impact of serum glucose in the treatment of locoregionally advanced pancreatic cancer
American Journal of Clinical Oncology Aug 30, 2019
Iarrobino NA, et al. - In this retrospective study involving 303 patients, researchers assessed the effect of glycemic state and antidiabetics on outcomes after systemic and local treatment for locoregionally advanced pancreatic cancer. The study sample consisted of patients with newly diagnosed advanced-stage pancreatic cancer treated from 2004 to 2014. They used the Kaplan-Meier survival analysis method to estimate time to event for overall survival, distant metastasis, and locoregional control. In multivariable analysis, a pretreatment glucose value ≥ 200 mg/dL was linked to increased mortality. Glucose ≥ 200 mg/dL before local treatment was linked to decreased overall survival after conditional analysis. Findings suggested an association of elevated blood glucose before treatment of locoregionally advanced pancreatic cancer with poorer results. In future clinical trial design, these findings should be included.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins